Brennan F M, Chantry D, Turner M, Foxwell B, Maini R, Feldmann M
Charing Cross-Sunley Research Centre, London, England.
Clin Exp Immunol. 1990 Aug;81(2):278-85. doi: 10.1111/j.1365-2249.1990.tb03331.x.
The presence of transforming growth factor-beta (TGF-beta) in inflammatory joint disease was investigated. Synovial fluid from patients with rheumatoid arthritis (RA) and patients with other non-autoimmune inflammatory joint diseases contained high levels of both active and latent TGF-beta. Levels of active TGF-beta did not correlate with drug regimen in either patient group or with the recovery period in the individuals with non-RA joint disease. Freshly isolated synovial cells from individuals with RA were shown by Northern blotting to express the mRNA for TGF-beta 1 and to secrete latent TGF-beta protein which could be neutralized by antibodies to TGF-beta 1 and TGF-beta 2. Lipopolysaccharide-stimulated peripheral blood mononuclear cells from normal donors produced interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-alpha) which was inhibited by pretreatment of these cells with recombinant TGF-beta. Cytokine production was not inhibited if the addition of TGF-beta was used after the inducing stimulus, suggesting that in activated cells cytokine production cannot be inhibited. This was confirmed by the observation that neither TGF-beta 1 or TGF-beta 2 inhibited spontaneous IL-1 or TNF-alpha production by rheumatoid synovial mononuclear cells in culture. These findings show that despite the presence of active TGF-beta in RA synovial joints and the spontaneous production of latent (potentially active) TGF-beta by RA cells in culture, additional TGF-beta did not inhibit ongoing cytokine synthesis in vitro. This suggests that TGF-beta may not inhibit cytokine production in the rheumatoid joint although it cannot be ruled out that in vivo TGF-beta already has an immunosuppressive effect which cannot be further increased in vitro by exogenous protein.
对炎症性关节疾病中转化生长因子-β(TGF-β)的存在情况进行了研究。类风湿关节炎(RA)患者和其他非自身免疫性炎症性关节疾病患者的滑液中,活性和潜伏性TGF-β水平均较高。活性TGF-β水平在两组患者中均与药物治疗方案无关,在非RA关节疾病患者中也与恢复期无关。通过Northern印迹法显示,从RA患者新鲜分离的滑膜细胞表达TGF-β1的mRNA,并分泌可被抗TGF-β1和TGF-β2抗体中和的潜伏性TGF-β蛋白。来自正常供体的脂多糖刺激的外周血单核细胞产生白细胞介素-1(IL-1)和肿瘤坏死因子-α(TNF-α),用重组TGF-β预处理这些细胞可抑制其产生。如果在诱导刺激后添加TGF-β,则细胞因子的产生不会受到抑制,这表明在活化细胞中细胞因子的产生无法被抑制。类风湿滑膜单核细胞在培养中自发产生IL-1或TNF-α,TGF-β1或TGF-β2均不能抑制这一现象证实了这一点。这些发现表明,尽管RA滑膜关节中存在活性TGF-β,且培养的RA细胞可自发产生潜伏性(潜在活性)TGF-β,但额外添加的TGF-β在体外并未抑制正在进行的细胞因子合成。这表明TGF-β可能不会抑制类风湿关节中的细胞因子产生,尽管不能排除体内TGF-β已经具有免疫抑制作用,且体外添加外源性蛋白无法进一步增强这种作用。